Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 12/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.42 |
| ▸ | CTSB | P07858 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140093 | 1.00 | ELOVL6 (0.44) | ELOVL6CTSSCTSLCTSBALDH1A1 | |
| SCHEMBL1139404 | 1.00 | ELOVL6 (0.44) | ELOVL6CTSSCTSLCTSBALDH1A1 | |
| SCHEMBL28039072 | 0.80 | ALDH1A1 (0.51) | ELOVL6CTSSCTSLCTSBALDH1A1 | |
| SCHEMBL3223437 | 0.72 | HTR6 (0.47) | ELOVL6CTSSALDH1A1L3MBTL1HTR2A | |
| SCHEMBL1140214 | 0.72 | CTSS (0.43) | ELOVL6CTSSCTSLCTSBALDH1A1 | |
| SCHEMBL3798952 | 0.72 | CTSS (0.43) | ELOVL6CTSSCTSLCTSBALDH1A1 | |
| SCHEMBL3798988 | 0.72 | CTSS (0.43) | ELOVL6CTSSCTSLCTSBALDH1A1 | |
| SCHEMBL3797176 | 0.72 | CTSS (0.43) | ELOVL6CTSSCTSLCTSBALDH1A1 | |
| SCHEMBL1139591 | 0.71 | CTSS (0.45) | ELOVL6CTSSCTSLCTSB | |
| SCHEMBL1139758 | 0.71 | AKR1C3 (0.45) | ELOVL6CTSSCTSLCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | ELOVL6 2985/4885CTSS 2367/4885CTSL 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.